Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

NCT07098338 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07098338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07098338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
August 7, 2025
Completion date
April 6, 2029
Enrollment
278 (estimated)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer